◎ Sugi Atlas

Atlas / Drug / Pyrimethamine

Pyrimethamine

drug
On this page

Also known as ChloridineDaraprimGNF-PF-5586MalacideNSC-3061PirimetaminaPyrimethamine component of fansidarPyrimethaminumRP-4753TCMDC-123831TCMDC-125860WR-2978PYRSID11112140SID17389746SID26747011SID855854SID56422411SID104171273

Summary

Pyrimethamine (CHEMBL36) is an approved small-molecule EC 1.5.1.3 (dihydrofolate reductase) inhibitor (ATC P01BD01) targeting SLC47A1 and SLC47A2; indicated across 23 conditions including malaria and toxoplasmosis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: P01BD01 (+1 more)
  • Targets: 2 (SLC47A1, SLC47A2)
  • Indications: 23 conditions
  • Clinical trials: 51
  • Chemistry: 248.71 Da · C12H13ClN4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL36
NamePyrimethamine
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID4993
ChEBICHEBI:8673
ATCP01BD01, P01BD51
Molecular formulaC12H13ClN4
Molecular weight248.71
InChIKeyWKSAUQYGYAYLPV-UHFFFAOYSA-N

SMILES: CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl

IUPAC name: 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine

ChEBI definition: An aminopyrimidine that is pyrimidine-2,4-diamine which is substituted at position 5 by a p-chlorophenyl group and at position 6 by an ethyl group. It is a folic acid antagonist used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

Pharmacological roles (ChEBI): antimalarial, EC 1.5.1.3 (dihydrofolate reductase) inhibitor, antiprotozoal drug.

Also known as: Chloridine, Daraprim, GNF-PF-5586, Malacide, NSC-3061, Pirimetamina, Pyrimethamine, Pyrimethamine component of fansidar, Pyrimethaminum, RP-4753, TCMDC-123831, TCMDC-125860

Patent coverage: 6,205 distinct patent families (19,344 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 19,292 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
SLC47A1Multidrug and toxin extrusionInhibition7.10.5%Q96FL8
SLC47A2MATE2Inhibition6.30.6%Q86VL8
Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase5.17

Broader ChEMBL bioactivity targets: 36 (assay-derived). Sample: Dihydrofolate reductase, Tyrosyl-DNA phosphodiesterase 1, Bifunctional dihydrofolate reductase-thymidylate synthase, Beta-hexosaminidase subunit alpha, Streptokinase A, Survival motor neuron protein, Prelamin-A/C, Dihydrofolate reductase, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Dihydrofolate reductase, Bifunctional dihydrofolate reductase-thymidylate synthase, Dihydrofolate reductase, Solute carrier family 22 member 1, Menin/Histone-lysine N-methyltransferase MLL, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, Alpha-1A adrenergic receptor, Dihydrofolate reductase, Dihydrofolate reductase.

Bioactivity

ChEMBL activities: 115 potent at pChembl ≥ 5 of 137 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
P139229.72Ki0.19nMCHEMBL_ACT_1203299
P139229.22Ki0.6nMCHEMBL_ACT_1135242
P139229.22Ki0.6nMCHEMBL_ACT_955201
P139229.06Ki0.87nMCHEMBL_ACT_1464730
P0ABQ48.92Ki1.2nMCHEMBL_ACT_1203298
P0ABQ48.85Kd1.4nMCHEMBL_ACT_1203292
P139228.85Ki1.4nMCHEMBL_ACT_797696
P0ABQ48.82Kd1.5nMCHEMBL_ACT_1203290
P139228.82Ki1.5nMCHEMBL_ACT_220986
P139228.82Ki1.5nMCHEMBL_ACT_797694
P139228.7Ki2nMCHEMBL_ACT_1203300
P139228.44Ki3.6nMCHEMBL_ACT_797697
P0ABQ48.28Ki5.2nMCHEMBL_ACT_1203296
P139228.28IC505.25nMCHEMBL_ACT_28871372
P139228.22Ki6nMCHEMBL_ACT_797695
DHFR8.1Ki8nMCHEMBL_ACT_955214
P161848.01Ki9.7nMCHEMBL_ACT_80276
P0ABQ48Ki10nMCHEMBL_ACT_1203295
DHFR7.96Ki11nMCHEMBL_ACT_225849
P0ABQ47.89Kd13nMCHEMBL_ACT_1203289
P0ABQ47.8Kd16nMCHEMBL_ACT_1203291
P0ABQ47.7Ki20nMCHEMBL_ACT_1203297
P139227.59IC5025.5nMCHEMBL_ACT_18465860
DHFR7.55Ki28.2nMCHEMBL_ACT_18946332
DHFR7.55Ki28.3nMCHEMBL_ACT_19288990
P139227.54Ki28.6nMCHEMBL_ACT_955203
DHFR7.51Ki30.8nMCHEMBL_ACT_3514330
P139227.27Ki53.9nMCHEMBL_ACT_955206
P139227.24IC5058nMCHEMBL_ACT_18465802
P139227.17Ki67.1nMCHEMBL_ACT_1135243
P139227.14Ki71.7nMCHEMBL_ACT_220987
P139227.1IC5080nMCHEMBL_ACT_1135249
P139227.1IC5080nMCHEMBL_ACT_1751611
Q074227.1IC5080nMCHEMBL_ACT_2559293
DHFR7.01Ki98nMCHEMBL_ACT_225848
P003767IC50100.7nMCHEMBL_ACT_18210700
P003767IC50100.7nMCHEMBL_ACT_18259256
P139226.95Ki112nMCHEMBL_ACT_1135245
DHFR6.92Ki120nMCHEMBL_ACT_225850
Q074226.86IC50139nMCHEMBL_ACT_19365591
P003766.85IC50141nMCHEMBL_ACT_25601702
Q8K0H16.84Ki145nMCHEMBL_ACT_13853423
Q074226.7IC50200nMCHEMBL_ACT_10944969
Q074226.64IC50230nMCHEMBL_ACT_16793600
DHFR6.6Ki250nMCHEMBL_ACT_225847
P0ABQ46.55Ki281.8nMCHEMBL_ACT_1168173
P139226.42Ki385nMCHEMBL_ACT_1135247
P139226.42Ki380nMCHEMBL_ACT_797698
Q074226.41IC50390nMCHEMBL_ACT_1040396
Q074226.41IC50390nMCHEMBL_ACT_1261656
Q074226.41IC50390nMCHEMBL_ACT_177406
Q074226.41IC50390nMCHEMBL_ACT_228327
Q074226.41IC50390nMCHEMBL_ACT_256272
Q074226.41IC50390nMCHEMBL_ACT_560129
Q074226.41IC50390nMCHEMBL_ACT_661044
Q074226.41IC50390nMCHEMBL_ACT_990668
DHFR6.4IC50400nMCHEMBL_ACT_13297380
DHFR6.33Ki470nMCHEMBL_ACT_18251963
KCNH26.19AC50649nMCHEMBL_ACT_25118001
DHFR6.12IC50760nMCHEMBL_ACT_19365657
P139226.07Ki860nMCHEMBL_ACT_797699
Q277936IC501000nMCHEMBL_ACT_28871174
Q920D25.85IC501400nMCHEMBL_ACT_600941
Q920D25.82IC501500nMCHEMBL_ACT_13297296
Q920D25.82IC501500nMCHEMBL_ACT_177404
DHFR5.78IC501680nMCHEMBL_ACT_19365560
SMN15.75Potency1778nMCHEMBL_ACT_3890837
P0ABQ45.7IC502000nMCHEMBL_ACT_2559273
SLC6A35.66AC502200nMCHEMBL_ACT_25124042
Q920D25.64IC502300nMCHEMBL_ACT_1040395
Q920D25.64IC502300nMCHEMBL_ACT_1261654
Q920D25.64IC502300nMCHEMBL_ACT_228326
Q920D25.64IC502300nMCHEMBL_ACT_256270
Q920D25.64IC502300nMCHEMBL_ACT_661043
Q920D25.64IC502300nMCHEMBL_ACT_80277
Q920D25.64IC502300nMCHEMBL_ACT_990666
P161845.62IC502400nMCHEMBL_ACT_13297324
P161845.62IC502400nMCHEMBL_ACT_177405
DHFR5.58IC502600nMCHEMBL_ACT_515175
P161845.55IC502800nMCHEMBL_ACT_80275
HEXA5.51IC503100nMCHEMBL_ACT_15606671
P161845.44IC503650nMCHEMBL_ACT_1040394
O089665.44Ki3600nMCHEMBL_ACT_13853422
P161845.44IC503650nMCHEMBL_ACT_228325
P161845.43IC503700nMCHEMBL_ACT_1261655
P161845.43IC503700nMCHEMBL_ACT_256271
P161845.43IC503700nMCHEMBL_ACT_990667
ADRA1A5.4AC504000nMCHEMBL_ACT_25137991
P105205.4EC503992nMCHEMBL_ACT_4885730
DHFR5.39IC504074nMCHEMBL_ACT_28871171
DHFR5.39IC504074nMCHEMBL_ACT_28871237
DHFR5.39IC504074nMCHEMBL_ACT_28871303
DHFR5.39IC504074nMCHEMBL_ACT_28871369
DHFR5.38IC504169nMCHEMBL_ACT_28870871
DHFR5.37IC504300nMCHEMBL_ACT_16793576
HEXB5.35IC504500nMCHEMBL_ACT_15606669
HTR2A5.35AC504432nMCHEMBL_ACT_25173653
CYP3A45.3Potency5012nMCHEMBL_ACT_4993868
CYP3A45.3Potency5012nMCHEMBL_ACT_5059011
P229065.3IC505000nMCHEMBL_ACT_515174

Target pathways

Aggregated over 2 target gene(s): SLC47A1, SLC47A2.

Top Reactome pathways

4 total, by targets touching each:

PathwayTargetsGenes
Transport of small molecules2SLC47A1, SLC47A2
R-HSA-4253662SLC47A1, SLC47A2
SLC-mediated transmembrane transport2SLC47A1, SLC47A2
SLC-mediated transport of organic cations2SLC47A1, SLC47A2

Dominant GO biological processes

GO termTargets
obsolete organic cation transport2
transmembrane transport2
xenobiotic detoxification by transmembrane export across the plasma membrane2
proton transmembrane transport2
xenobiotic transmembrane transport1
putrescine transport1
xenobiotic transport1
amino acid import across plasma membrane1
L-arginine import across plasma membrane1
L-alpha-amino acid transmembrane transport1
thiamine transmembrane transport1
monoatomic cation transmembrane transport1
L-arginine transmembrane transport1

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
malaria4MONDO:0005136EFO:0001068
toxoplasmosis4MONDO:0005989EFO:0007517

16 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
anemia3MONDO:0002280EFO:0004272
congenital toxoplasmosis3MONDO:0005715EFO:0007220
Plasmodium falciparum malaria3MONDO:0005920EFO:0007444
Plasmodium vivax malaria3MONDO:0005921EFO:0007445
schistosomiasis3MONDO:0015254EFO:1001475
HIV infectious disease3MONDO:0005109EFO:0000180
pneumocystosis3MONDO:0019121EFO:0007448
chorioretinitis3MONDO:0004674HP:0012424
depressive disorder3MONDO:0002050MONDO:0002050
cerebral toxoplasmosis2MONDO:0005697EFO:0007200
familial amyotrophic lateral sclerosis1MONDO:0005144EFO:0001356
B-cell chronic lymphocytic leukemia1MONDO:0004948EFO:0000095
myelodysplastic syndrome1MONDO:0018881EFO:0000198
Sandhoff disease1MONDO:0010006MONDO:0010006
Tay-Sachs disease1MONDO:0010100MONDO:0010100
GM2 gangliosidosis1MONDO:0017720MONDO:0017720

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 51.

Phase distribution

PhaseTrials
Not specified14
PHASE311
PHASE110
PHASE46
PHASE1/PHASE26
PHASE22
PHASE2/PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00004317PHASE4RECRUITINGPyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
NCT00125489PHASE4COMPLETEDCQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi
NCT00164255PHASE4COMPLETEDEfficacy of Combination Therapy for Prevention of Effects of Malaria During Pregnancy
NCT00453856PHASE4TERMINATEDEfficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children
NCT05478954PHASE4UNKNOWNChemoprevention Efficacy Study in Burkina Faso
NCT05980156PHASE4COMPLETEDComparing Chemoprevention Drugs for School-based Malaria Control
NCT00000727PHASE3COMPLETEDA Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)
NCT00123552PHASE3COMPLETEDLongitudinal Antimalarial Combinations in Uganda
NCT00132548PHASE3COMPLETEDA Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children
NCT00146718PHASE2/PHASE3COMPLETEDAnti-Malarial Drug Resistance in Cameroon
NCT00299247PHASE3WITHDRAWNSP Resistance and Falciparum Malaria Transmission
NCT00300404PHASE3COMPLETEDEffect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
NCT00361114PHASE3TERMINATEDIPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria.
NCT00399074PHASE3COMPLETEDSulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia
NCT01054651PHASE3COMPLETEDA Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni
NCT01189448PHASE3COMPLETEDPrevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy
NCT04783051PHASE3COMPLETEDComparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)
NCT05471544PHASE3UNKNOWNEffectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in South Sudan
NCT07384624PHASE1/PHASE2NOT_YET_RECRUITINGCombining Latency Reversing Agents to Address the HIV Reservoir
NCT00000643PHASE2COMPLETEDPrimary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients
NCT00000794PHASE2COMPLETEDPhase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis
NCT01066663PHASE1/PHASE2COMPLETEDPyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT01083667PHASE1/PHASE2COMPLETEDSOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)
NCT01102686PHASE1/PHASE2COMPLETEDPyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)
NCT03525730PHASE1/PHASE2COMPLETEDLRAs United as a Novel Anti-HIV Strategy.
NCT03952650PHASE1/PHASE2COMPLETEDSanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa…
NCT00000966PHASE1COMPLETEDA Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS
NCT00000973PHASE1COMPLETEDA Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients
NCT00065390PHASE1COMPLETEDPyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
NCT00679744PHASE1WITHDRAWNA Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis
NCT01973933PHASE1COMPLETEDClinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction of Pyrimethamine and Metformin IR
NCT02511054PHASE1COMPLETEDSanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B…
NCT03057990PHASE1WITHDRAWNPyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)
NCT03083847PHASE1COMPLETEDDose Escalation PfSPZ-CVac
NCT03258762PHASE1COMPLETEDPhase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects
NCT04086719PHASE1COMPLETEDAn Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.
NCT05678348EARLY_PHASE1COMPLETEDPyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT05856357Not specifiedACTIVE_NOT_RECRUITINGPerennial Malaria Chemoprevention (PMC) in Côte D’Ivoire
NCT05889052Not specifiedACTIVE_NOT_RECRUITINGPerennial Malaria Chemoprevention (PMC) in Cameroon
NCT05949190Not specifiedACTIVE_NOT_RECRUITINGImproving Cognition and Gestational Duration With Targeted Nutrition
NCT00000666Not specifiedCOMPLETEDA Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection
NCT00000674Not specifiedCOMPLETEDA Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS
NCT00002064Not specifiedCOMPLETEDToxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
NCT00126906Not specifiedCOMPLETEDPrevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi
NCT00304980Not specifiedTERMINATEDComparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status
NCT00766662Not specifiedCOMPLETEDIntermittent Preventive Treatment in Infant in Mali
NCT00951106Not specifiedCOMPLETEDTherapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon
NCT03454048Not specifiedCOMPLETEDControlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
NCT03944317Not specifiedUNKNOWNAzithromycin (AZ) and Sulphadoxine-pyrimethamine (SP) for Malaria Prevention in Pregnant Women (IPT-AZ/IPT-SP)
NCT05354258Not specifiedUNKNOWNFeasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children
NCT06002438Not specifiedCOMPLETEDEggs for Gut Health

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 7 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

69 molecules share ≥1 primary target. Top 69 by shared-target count:

MoleculeSourceStatusShared targets
BUSPIRONEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
CARVEDILOLChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
CHLORHEXIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
CIMETIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
DIHYDROERGOTAMINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
DIPYRIDAMOLEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
DISOPYRAMIDEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
DOMPERIDONEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
EPINASTINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
ETHINYL ESTRADIOLChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
FAMOTIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
IMATINIBChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
IMIPRAMINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
IRINOTECANChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
MITOXANTRONEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
ONDANSETRONChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
ORPHENADRINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
PANTOPRAZOLEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
PENTAMIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
PRAZOSINChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
QUINIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
RIMANTADINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
RISPERIDONEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
RITONAVIRChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
TOPOTECANChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
TUBOCURARINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
VECURONIUM BROMIDEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
ZAFIRLUKASTChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
BITHIONOLChEMBLPhase 4 (approved)SLC47A1, SLC47A2
DABIGATRANChEMBL + PubChemPhase 3 (approved)SLC47A1, SLC47A2
CAMOSTATChEMBLPhase 3SLC47A1, SLC47A2
GABEXATEChEMBLPhase 3SLC47A1, SLC47A2
INDINAVIRChEMBLPhase 3SLC47A1, SLC47A2
NIFEKALANTChEMBLPhase 3SLC47A1, SLC47A2
AripiprazolePubChemApprovedSLC47A1, SLC47A2
MetforminPubChemApprovedSLC47A1, SLC47A2
PimozidePubChemApprovedSLC47A1, SLC47A2
AMANTADINEChEMBL + PubChemPhase 4 (approved)SLC47A1
CLONIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1
SPIRONOLACTONEChEMBL + PubChemPhase 4 (approved)SLC47A1
SUMATRIPTANChEMBL + PubChemPhase 4 (approved)SLC47A1
TELMISARTANChEMBL + PubChemPhase 4 (approved)SLC47A1
ASTEMIZOLEChEMBLPhase 4 (approved)SLC47A1
GRANISETRONChEMBLPhase 4 (approved)SLC47A1
LEVOFLOXACINChEMBLPhase 4 (approved)SLC47A1
MARAVIROCChEMBLPhase 4 (approved)SLC47A1
NOSCAPINEChEMBLPhase 4 (approved)SLC47A1
RANITIDINEChEMBLPhase 4 (approved)SLC47A1
TACRINEChEMBLPhase 4 (approved)SLC47A1
CORTISONEChEMBL + PubChemPhase 3 (approved)SLC47A1
AFIMETORANChEMBLPhase 2SLC47A2
azacitidinePubChemApprovedSLC47A1
CetirizinePubChemApprovedSLC47A1
CiclopiroxPubChemApprovedSLC47A1
DexamethasonePubChemApprovedSLC47A1
DiclofenacPubChemApprovedSLC47A1
EnalaprilPubChemApprovedSLC47A1
ErythromycinPubChemApprovedSLC47A1
FurosemidePubChemApprovedSLC47A1
IndomethacinPubChemApprovedSLC47A1
IrbesartanPubChemApprovedSLC47A1
LidocainePubChemApprovedSLC47A1
LosartanPubChemApprovedSLC47A1
methylergonovinePubChemApprovedSLC47A1
niacinPubChemApprovedSLC47A1
PramipexolePubChemApprovedSLC47A2
ProcainamidePubChemApprovedSLC47A1
SulfacetamidePubChemApprovedSLC47A1
ThiabendazolePubChemApprovedSLC47A1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot